Amgen: Are Its Golden Days Over? | FAST Graphs

[@svenhonkomp749]

i like Amgen but i loading up on UGI at the moment. For me is also BMY a buy to get more Shares then Amgen,but everyone has a different plan and Chuck Show us all how to look at a Stock and to Value it. Always Amazing

[@joannekelleher1859]

As a biomedical scientist who has held AMGN since its early, EPO, days, I would like to draw attention to an important compound in AMGN pipeline, AMG-133, an anti-obesity drug in phase II trials. AMG-133 would compete with the new drugs such as Lilly’s highly effective Mounjaro. AMGN approach is different. Technically they include an antagonist for an important gut hormone receptor, GIP, while Lilly and others do the opposite, they agonize, or promote, GIP. The jury is out on the best approach but I will be watching to see if AMGN can produce an effective obesity drug. If AMGN management is betting big on ANG-133 could this explain share buy backs?

[@FASTgraphs]

Thanks for your professional input

[@tdiler12]

this is all fantastic technical & fundamental analysis however, none of it matters if Amgen comes up with a promising weight loss candidate the stock will skyrocket that’s all Wall street cares about right now from big Pharma

[@voimakyykky3980]

Been eyeing this one, very helpful. Thanks! Could you make a update on CVS?

[@profitbear7337]

Yes, Chuck. Please! Would love an update on CVS

[@Arun24986]

This is an amazing combo of father and son. God bless you and Colton!

[@wojaksformula9157]

please analyze BMY stock

[@basti1993x]

I would like to request the UnitedHealth Group, thanks in advance.

[@yaykruser]

Oh yeah, having an eye on it too, but it still looks overpriced...

[@jjsheets330]

Uncle Chuck and Colton = the Batman and Robin of KZbin finance

[@jameslong7365]

Awesome father-and-son combo video! I love both the illustrative way Chuck used Fast Graph to think, as well as Colt's forensic analysis of the company. An instructive video, And the teaser at the end of the video... :-) I for one will be looking forward to the updates so I can "fully participate in the growth of the company"!

[@chuckdiezel7652]

Excellent call out that shareholder value is getting wrecked due to buybacks fueled by debt. It’s ok when interest rates are zero but questionable if continues

[@deanaz41]

Fast Graphs subscriber here. As of 7/7/23 I’m buying UNH and ELV. Chuck, give us a video on ELV, it’s a bargain

[@mrmurky1118]

I’m loving Amgen. Amazing stock.

[@joachims.334]

Another great video, thanks to the both of you. I have made a decision for my personal portfolio to not add any more companies with sketchy balance sheets. (I still have a few that are under constant surveillance.) Amgen is one of those that looks attractive but seems very strongly leveraged. It's not for me.

[@ivanxyz1]

I really like the analysis with graphs and the deep dive into the financials. Great job!

[@pzeid48]

Good Video as always. I would love to see your review on some European, especially German stocks (if they are covered by the tool). Especially Allianz SE, Infineon, Munich RE, Hannoversche Rück, the automobile companies and maybe the European juggernauts in luxury and health/consumerism.

[@davidscott7682]

Another great and informative video Chuck & Colton. Being a new subscriber, I appreciate the improvements I see in the content of the videos: Chuck reviewing the various time frames and how that impacts future growth and Colton educating us on how to pull data from the balance sheet & cash flow statement to further our DD on stocks.....all great stuff. I am still concerned with that projected cash flow drop in 2025.....did I miss that explanation in the video? Thanks

[@FASTgraphs]

As you pointed out that is a "projected" drop and we are looking into it. We want to be sure that it is not a simple data error, or just some radical analysts opinion.

[@hansschotterradler3772]

Thanks for this great video. Wish I had sold this last Fall.

[@Dhi-fe5eu]

If AMGN drops to $200. Which it could when interest rates go up next week. I will buy it up.

[@stuartm8720]

Great educational video for analysis

[@JJJ5.7]

Thanks Chuck, this is one of those 'should I sell' examples I've asked you about in the past. I've owned this one for probably 20 years. If I sell I incur big capital gains taxes. Or do I just hold onto what I have for the dividends? So far, I'm holding on even though its lost money over the last year or two and other issues you mention. Sometimes decision is not so simple.

[@FASTgraphs]

I don't see any reason to sell Amgen here, but you have to make that decision for yourself. Warren Buffett once said the best holding period is forever. Also, consider that the company hasn't had falling earnings or dividends only the price has changed and any losses you have are unrealized. Focus on what I spoke about what I was doing the forecasting calculators. Hope that helps, Chuck

[@JJJ5.7]

@@FASTgraphs thanks chuck.

[@HedgeFundOfOne]

With all the share buybacks, I would expect better growth rates in earnings- & cash flow-per-share as the denominator is being reduced. The pipeline really needs to come through with future profitable products.

[@seedbox7569]

Thank you for the video!

[@cris471]

Excellent !

[@harutyung3767]

Wow, amazing analysis

[@Jerseygirlinberkeley1]

I would like to request an analysis of SQM.

[@root123]

Fantastic

[@Orangejulius8]

Maybe I missed it, but I didn't hear it mentioned why AMGN took on all that debt to raise cash this year. It's for a $27.8B, all cash acquisition they're attempting for Horizon Therapeutics. (HZNP) That acquisition is in question now that the FTC sued to block it. AMGN debt was quite reasonable before that. They're betting big on Horizon, so considering Horizon's pipeline is of paramount importance if you're looking to invest in AMGN, since the popular view is the FTC will lose their lawsuit and AMGN will take on all of HZNP's products and pipeline.

[@FASTgraphs]

You will find a discussion of the Horizon therapeutics acquisition in the written portion by James Long: fastgraphs.com/blog/amgen-are...